---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-018914"
form_type: "8-K"
ticker: "MGTX"
cik: "0001735438"
company_name: "MeiraGTx Holdings plc"
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:50:22.533392+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# MeiraGTx reports Q3 net loss $44.3M; Sanofi invests $30M at $7.50/share

## Summary
- Sanofi purchased $30M of ordinary shares at $7.50/share; ROFN for Riboswitch platform on CNS, I&I, metabolic targets including GLP-1 and Xerostomia.
- Q3 net loss $44.3M ($0.74 per share) vs $37.3M ($0.83) prior year; license revenue $5.1M.
- R&D expenses rose 65% to $27.9M driven by manufacturing costs and Janssen collaboration changes.
- Cash $64.4M plus $22M Janssen receivables and $30M Sanofi investment; runway into mid-2025.
- Phase 3 XLRP trial fully enrolled with IND transferred to Janssen; Phase 2 Xerostomia and Parkinson's studies ongoing.

## SEC filing metadata
- accession: 0001558370-23-018914
- form_type: 8-K
- ticker: MGTX
- cik: 0001735438
- company_name: MeiraGTx Holdings plc
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1735438/000155837023018914/0001558370-23-018914-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1735438/000155837023018914/mgtx-20231114x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-018914
- JSON: https://secwatch.observer/filing/0001558370-23-018914.json
- Plain text: https://secwatch.observer/filing/0001558370-23-018914.txt

## Key facts
- Earnings Releases
  MeiraGTx Holdings plc reported the quarter ended September 30, 2023 results: revenue $5.1 million.
  - Period: the quarter ended September 30, 2023
  - Revenue: $5.1 million
  - Result: reported results
  source text: License revenue was $5.1 million for the quarter ended September 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1735438/000155837023018914/0001558370-23-018914-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.